Prevalence of Epstein-Barr Virus Latent Membrane Protein-1 in Jordanian Patients with Hodgkin's Lymphoma and Non- Hodgkin's Lymphoma
The aim of this study was to estimate the frequency of
EBV infection in Hodgkin's lymphoma (HL) and non-Hodgkin's
lymphoma (NHL) occurring in Jordanian patients. A total of 55
patients with lymphoma were examined in this study. Of 55 patients,
30 and 25 were diagnosed as HL and NHL, respectively. The four
HL subtypes were observed with the majority of the cases exhibited
the mixed cellularity (MC) subtype followed by the nodular sclerosis
(NS). The high grade was found to be the commonest subtype of
NHL in our sample, followed by the low grade. The presence of EBV
virus was detected by immunostating for expression of latent
membrane protein-1 (LMP-1). The frequency of LMP-1 expression
occurred more frequent in patients with HL (60.0%) than in patients
with NHL (32.0%). The frequency of LMP-1 expression was also
higher in patients with MC subtype (61.11%) than those patients with
NS (28.57%). No age or gender difference in occurrence of EBV
infection was observed among patient with HL. By contrast, the
prevalence of EBV infection in NHL patients aged below 50 was
lower (16.66%) than in NHL patients aged 50 or above (46.15%). In
addition, EBV infection was more frequent in females with NHL
(38.46%) than in male with NHL (25%). In NHL cases, the
frequency of EBV infection in intermediate grade (60.0%) was high
when compared with frequency of low (25%) or high grades (25%).
In conclusion, analysis of LMP-1 expression indicates an important
role for this viral oncogene in the pathogenesis of EBV-associated
malignant lymphomas. These data also support the previous findings
that people with EBV may develop lymphoma and that efforts to
maintain low lymphoma should be considered for people with EBV
infection.
[1] N. L. Harris, E. S. Jaffe and J. O. Armitage, et al., "Lymphoma
classification: from R.E.A.L. to W.H.O. and beyond," Cancer: Principles
and Practice of Oncology Updates, vol. 13, pp. 1-14, 1999.
[2] J. Stjernswa¨rd, F. Ferris, S. Khleif, W. Jamous, I. Treish, M. Milhem,
M. Bushnaq, A. Al Khateib, N. Al-Shtiat, M. Wheeler, and A. Alwan,
"Jordan palliative care initiative: A WHO demonstration project,"
Journal of Pain and Symptom Management, vol. 33, pp. 628-633, 2007.
[3] A. Jemal, A. Thomas, T. Murray, and M. Thun, "Cancer statistics CA,"
Cancer J. Clin. Vol. 52, pp. 23-47, 2002.
[4] J. G. Gribben, "How I treat indolent lymphoma," Blood, vol. 109, pp.
4617-4626, 2002.
[5] L. B. Travis, "Evaluation of the risk of therapy-associated complications
in survivors of Hodgkin Lymphoma," Hematology, vol. 1, pp. 192-196,
2007.
[6] J. S. Knight, A. Tsodikov, D. M. Cibrik, C. W. Ross, M. S. Kaminski,
and D. W. Blayney, "Lymphoma after solid organ transplantation: Risk,
response to therapy, and survival at a transplantation center," J. Clin.
Oncol., vol. 27, pp. 3354-3362, 2009.
[7] K. Hemminki, P. Lenner, J. Sundquist, and J. L. Bermejo, "Risk of
subsequent solid tumors after non-Hodgkin's lymphoma: Effect of
diagnostic age and time since diagnosis," J. Clin. Oncol., vol. 26, pp.
1850-1857, 2008.
[8] S. B. Pattle, and P. J. Farrell, "The role of Epstein-Barr virus in cancer,"
Expert Opin. Biol. Ther., Vol. 6, pp. 1193-1205, 2006.
[9] D. Serraino, P. Piselli, C. Angeletti, M. Scuderi, and M. R. Ippolito,
"Infection with Epstein-Barr virus and cancer: an epidemiological
review," J. Biol. Regul. Homeost. Agents, vol. 19, pp. 63-70, 2005.
[10] J. I. Cohen, "Epstein-Barr virus infection," N. Engl. J. Med., vol. 343,
pp. 481-492, 2000.
[11] G. Kapatai, and P. Murray, "Contribution of the Epstein Barr virus to the
molecular pathogenesis of Hodgkin lymphoma," J. Clin. Pathol., vol. 60,
pp. 1342-1349, 2007.
[12] D. A. Thorley-Lawson, and A. Gross, "Persistence of the Epstein-Barr
virus and the origins of associated lymphomas," N. E. J. M., vol. 350,
pp. 1328-1337, 2004.
[13] L. H. Kim, S. C. Peh, and S. Poppema, "Expression of retinoblastoma
protein and p16 proteins in classic Hodgkin's lymphoma: relationship
with expression of p53 and presence of Epstein-Barr virus in the
regulation of cell growth and death," Journal of Human Pathology, vol.
37, pp. 92-100, 2006.
[14] P. Zhao, Y. Lu, L. Liu, and M. Zhong, "Aberrant expression of ID2
protein and its correlation with EBV-LMP1 and p16 (INK4A) in
Classical Hodgkin's Lymphoma in China," BioMed Central journal, vol.
8, pp. 1471-2407, 2008.
[15] L. M. Staudt, "The molecular and cellular origins of Hodgkin-s disease,"
The Journal of Experimental Medicine, vol. 191, pp. 207-212, 2002.
[16] W. J. Haddadin, "Malignant lymphoma in Jordan: a retrospective
analysis of 347 cases according to the World Health Organization
classification," Annals of Saudi Medicine, vol. 25, pp. 398-403, 2005.
[17] S. Bamanikar, S. Thunold, K. R. Devi, and A. Bamanikar, "The pattern
of malignant lymphoma in Oman," Tropical Medicine and Hygiene
Journal, vol. 98, pp. 351-354, 1995.
[18] D. K. Shome, S. M. George, F. Al-Hilli, and A. A. Satir, "Spectrum of
malignant lymphomas in Bahrain. Leitmotif of a regional pattern," Saudi
Medicine Journal, vol. 25, pp. 146-167, 2004.
[19] A. Castella, S. Joshi, T. Raaschou, and N. Mason, "Pattern of Malignant
Lymphoma in the United Arab Emirates," Acta Oncologica, vol. 40, pp.
660-664, 2001.
[20] A. S. Soliman, and P. Boffetta, "lymphoma and leukemia," Middle East
Cancer Consortium (MECC) Registries, 2004.
[21] N. M. Almasri, "Hodgkin-s lymphoma in north Jordan. Does it have
different pattern," Saudi Medical Journal, vol. 25, pp. 1971-1921, 2004.
[22] W. K. Ridha, "Epstein Barr Virus-Mediated deregulation of cell cycle
pathways in malignant lymphomas: implication of NFKB, p53, p27 and
the mutant p21 Ras using in situ technique," Ph. D. Thesis, University of
AL-Nahrain, Iraq, 2004.
[23] S. A. Pileri, S. Ascani, L. Leoncini, E. Sabattini, P. L. Zinzani, P. P.
Piccaluga, A. Pileri, M. Giunti, B. Falini, G. B. Bolis, and H. Stein,
"Hodgkin-s lymphoma: the pathologist-s viewpoint," Journal of Clinical,
vol. 55, pp. 162-176, 2002.
[24] J. O. Thomas, and M. A. Abdullah, "Malignant lymphoma in western
province of Saudi Arabia," East African Medical Journal, vol. 72, pp.
355-358, 1995.
[25] J. Vassallo, K. Metze, F. Traina, C. de Souza, and I. Lorand-Metze,
"Expression of Epstein-Barr virus in classical Hodgkin-s lymphomas in
Brazilian adult patients," Haematologica, vol. 86, pp.1227-1228, 2001.
[26] S. Bossolasco, P. Cinque, M. Ponzoni, M. G. Vigano, A. Lazzarin, A.
Linde, and K. I. Falk, "Epstein-Barr virus DNA load in cerebrospinal
fluid and plasma of patients with AIDS-related lymphoma," Journal of
NeuroVirology, vol. 8, pp. 432- 438, 2002.
[27] C. R. Rao, M. I. Gutierrez, K. Bhatia, F. Fend, J. Franklin, L. Appaji, G.
Gallo, G. Oconor, N. Lalitha, and I. Magrath, "Association of Burkitt-s
lymphoma with the Epstein-Barr virus in two developing countries,"
Leukemia and Lymphoma, vol. 39, pp. 329-337, 2002.
[1] N. L. Harris, E. S. Jaffe and J. O. Armitage, et al., "Lymphoma
classification: from R.E.A.L. to W.H.O. and beyond," Cancer: Principles
and Practice of Oncology Updates, vol. 13, pp. 1-14, 1999.
[2] J. Stjernswa¨rd, F. Ferris, S. Khleif, W. Jamous, I. Treish, M. Milhem,
M. Bushnaq, A. Al Khateib, N. Al-Shtiat, M. Wheeler, and A. Alwan,
"Jordan palliative care initiative: A WHO demonstration project,"
Journal of Pain and Symptom Management, vol. 33, pp. 628-633, 2007.
[3] A. Jemal, A. Thomas, T. Murray, and M. Thun, "Cancer statistics CA,"
Cancer J. Clin. Vol. 52, pp. 23-47, 2002.
[4] J. G. Gribben, "How I treat indolent lymphoma," Blood, vol. 109, pp.
4617-4626, 2002.
[5] L. B. Travis, "Evaluation of the risk of therapy-associated complications
in survivors of Hodgkin Lymphoma," Hematology, vol. 1, pp. 192-196,
2007.
[6] J. S. Knight, A. Tsodikov, D. M. Cibrik, C. W. Ross, M. S. Kaminski,
and D. W. Blayney, "Lymphoma after solid organ transplantation: Risk,
response to therapy, and survival at a transplantation center," J. Clin.
Oncol., vol. 27, pp. 3354-3362, 2009.
[7] K. Hemminki, P. Lenner, J. Sundquist, and J. L. Bermejo, "Risk of
subsequent solid tumors after non-Hodgkin's lymphoma: Effect of
diagnostic age and time since diagnosis," J. Clin. Oncol., vol. 26, pp.
1850-1857, 2008.
[8] S. B. Pattle, and P. J. Farrell, "The role of Epstein-Barr virus in cancer,"
Expert Opin. Biol. Ther., Vol. 6, pp. 1193-1205, 2006.
[9] D. Serraino, P. Piselli, C. Angeletti, M. Scuderi, and M. R. Ippolito,
"Infection with Epstein-Barr virus and cancer: an epidemiological
review," J. Biol. Regul. Homeost. Agents, vol. 19, pp. 63-70, 2005.
[10] J. I. Cohen, "Epstein-Barr virus infection," N. Engl. J. Med., vol. 343,
pp. 481-492, 2000.
[11] G. Kapatai, and P. Murray, "Contribution of the Epstein Barr virus to the
molecular pathogenesis of Hodgkin lymphoma," J. Clin. Pathol., vol. 60,
pp. 1342-1349, 2007.
[12] D. A. Thorley-Lawson, and A. Gross, "Persistence of the Epstein-Barr
virus and the origins of associated lymphomas," N. E. J. M., vol. 350,
pp. 1328-1337, 2004.
[13] L. H. Kim, S. C. Peh, and S. Poppema, "Expression of retinoblastoma
protein and p16 proteins in classic Hodgkin's lymphoma: relationship
with expression of p53 and presence of Epstein-Barr virus in the
regulation of cell growth and death," Journal of Human Pathology, vol.
37, pp. 92-100, 2006.
[14] P. Zhao, Y. Lu, L. Liu, and M. Zhong, "Aberrant expression of ID2
protein and its correlation with EBV-LMP1 and p16 (INK4A) in
Classical Hodgkin's Lymphoma in China," BioMed Central journal, vol.
8, pp. 1471-2407, 2008.
[15] L. M. Staudt, "The molecular and cellular origins of Hodgkin-s disease,"
The Journal of Experimental Medicine, vol. 191, pp. 207-212, 2002.
[16] W. J. Haddadin, "Malignant lymphoma in Jordan: a retrospective
analysis of 347 cases according to the World Health Organization
classification," Annals of Saudi Medicine, vol. 25, pp. 398-403, 2005.
[17] S. Bamanikar, S. Thunold, K. R. Devi, and A. Bamanikar, "The pattern
of malignant lymphoma in Oman," Tropical Medicine and Hygiene
Journal, vol. 98, pp. 351-354, 1995.
[18] D. K. Shome, S. M. George, F. Al-Hilli, and A. A. Satir, "Spectrum of
malignant lymphomas in Bahrain. Leitmotif of a regional pattern," Saudi
Medicine Journal, vol. 25, pp. 146-167, 2004.
[19] A. Castella, S. Joshi, T. Raaschou, and N. Mason, "Pattern of Malignant
Lymphoma in the United Arab Emirates," Acta Oncologica, vol. 40, pp.
660-664, 2001.
[20] A. S. Soliman, and P. Boffetta, "lymphoma and leukemia," Middle East
Cancer Consortium (MECC) Registries, 2004.
[21] N. M. Almasri, "Hodgkin-s lymphoma in north Jordan. Does it have
different pattern," Saudi Medical Journal, vol. 25, pp. 1971-1921, 2004.
[22] W. K. Ridha, "Epstein Barr Virus-Mediated deregulation of cell cycle
pathways in malignant lymphomas: implication of NFKB, p53, p27 and
the mutant p21 Ras using in situ technique," Ph. D. Thesis, University of
AL-Nahrain, Iraq, 2004.
[23] S. A. Pileri, S. Ascani, L. Leoncini, E. Sabattini, P. L. Zinzani, P. P.
Piccaluga, A. Pileri, M. Giunti, B. Falini, G. B. Bolis, and H. Stein,
"Hodgkin-s lymphoma: the pathologist-s viewpoint," Journal of Clinical,
vol. 55, pp. 162-176, 2002.
[24] J. O. Thomas, and M. A. Abdullah, "Malignant lymphoma in western
province of Saudi Arabia," East African Medical Journal, vol. 72, pp.
355-358, 1995.
[25] J. Vassallo, K. Metze, F. Traina, C. de Souza, and I. Lorand-Metze,
"Expression of Epstein-Barr virus in classical Hodgkin-s lymphomas in
Brazilian adult patients," Haematologica, vol. 86, pp.1227-1228, 2001.
[26] S. Bossolasco, P. Cinque, M. Ponzoni, M. G. Vigano, A. Lazzarin, A.
Linde, and K. I. Falk, "Epstein-Barr virus DNA load in cerebrospinal
fluid and plasma of patients with AIDS-related lymphoma," Journal of
NeuroVirology, vol. 8, pp. 432- 438, 2002.
[27] C. R. Rao, M. I. Gutierrez, K. Bhatia, F. Fend, J. Franklin, L. Appaji, G.
Gallo, G. Oconor, N. Lalitha, and I. Magrath, "Association of Burkitt-s
lymphoma with the Epstein-Barr virus in two developing countries,"
Leukemia and Lymphoma, vol. 39, pp. 329-337, 2002.
@article{"International Journal of Biological, Life and Agricultural Sciences:58271", author = "Fawzi Irshaid and Adnan Jaran and Fatiha Dilmi and Khaled Tarawneh and Raji Hadeth and Ahad Al-Khatib", title = "Prevalence of Epstein-Barr Virus Latent Membrane Protein-1 in Jordanian Patients with Hodgkin's Lymphoma and Non- Hodgkin's Lymphoma", abstract = "The aim of this study was to estimate the frequency of
EBV infection in Hodgkin's lymphoma (HL) and non-Hodgkin's
lymphoma (NHL) occurring in Jordanian patients. A total of 55
patients with lymphoma were examined in this study. Of 55 patients,
30 and 25 were diagnosed as HL and NHL, respectively. The four
HL subtypes were observed with the majority of the cases exhibited
the mixed cellularity (MC) subtype followed by the nodular sclerosis
(NS). The high grade was found to be the commonest subtype of
NHL in our sample, followed by the low grade. The presence of EBV
virus was detected by immunostating for expression of latent
membrane protein-1 (LMP-1). The frequency of LMP-1 expression
occurred more frequent in patients with HL (60.0%) than in patients
with NHL (32.0%). The frequency of LMP-1 expression was also
higher in patients with MC subtype (61.11%) than those patients with
NS (28.57%). No age or gender difference in occurrence of EBV
infection was observed among patient with HL. By contrast, the
prevalence of EBV infection in NHL patients aged below 50 was
lower (16.66%) than in NHL patients aged 50 or above (46.15%). In
addition, EBV infection was more frequent in females with NHL
(38.46%) than in male with NHL (25%). In NHL cases, the
frequency of EBV infection in intermediate grade (60.0%) was high
when compared with frequency of low (25%) or high grades (25%).
In conclusion, analysis of LMP-1 expression indicates an important
role for this viral oncogene in the pathogenesis of EBV-associated
malignant lymphomas. These data also support the previous findings
that people with EBV may develop lymphoma and that efforts to
maintain low lymphoma should be considered for people with EBV
infection.", keywords = "Hodgkin lymphoma, Epstein Barr virus, hematoxylin, infection, LMP-1 expression.", volume = "4", number = "12", pages = "894-7", }
